Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype

2012 ◽  
Vol 7 (2) ◽  
pp. 443-450 ◽  
Author(s):  
Wenpeng Li ◽  
Nadia Warner ◽  
Vitina Sozzi ◽  
Lilly Yuen ◽  
Danni Colledge ◽  
...  
2007 ◽  
Vol 27 (1) ◽  
Author(s):  
Do Young Kim ◽  
Hong Jeoung Kim ◽  
Chun Kyon Lee ◽  
Jeong Hun Suh ◽  
Dong Hwan Kim ◽  
...  

Intervirology ◽  
2008 ◽  
Vol 51 (6) ◽  
pp. 385-393 ◽  
Author(s):  
Norio Akuta ◽  
Fumitaka Suzuki ◽  
Yusuke Kawamura ◽  
Hiromi Yatsuji ◽  
Hitomi Sezaki ◽  
...  

2017 ◽  
Vol 243 ◽  
pp. 20-24
Author(s):  
Xin Ji ◽  
Mohammad Zafrullah ◽  
Nicholas Wiese ◽  
Tonya Hayden-Mixon ◽  
Joseph C. Forbi ◽  
...  

2007 ◽  
Vol 152 (6) ◽  
pp. 1223-1228 ◽  
Author(s):  
S. Datta ◽  
P. K. Chandra ◽  
A. Banerjee ◽  
R. Chakravarty ◽  
K. M. Murhekar ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (7) ◽  
pp. e102573 ◽  
Author(s):  
Somenath Datta ◽  
Shrabasti Roychoudhury ◽  
Alip Ghosh ◽  
Debanjali Dasgupta ◽  
Amit Ghosh ◽  
...  

2013 ◽  
Vol 10 (1) ◽  
pp. 27 ◽  
Author(s):  
Marlinang D Siburian ◽  
Andi Utama ◽  
Rama Dhenni ◽  
null Arnelis ◽  
Ismail Fanany ◽  
...  

2010 ◽  
Vol 83 (2) ◽  
pp. 225-234 ◽  
Author(s):  
Juniastuti ◽  
Takako Utsumi ◽  
Victor Eka Nugrahaputra ◽  
Mochamad Amin ◽  
Soetjipto ◽  
...  

Virus Genes ◽  
2004 ◽  
Vol 29 (1) ◽  
pp. 31-41 ◽  
Author(s):  
Kangxian Luo ◽  
Zhihua Liu ◽  
Haitang He ◽  
Jie Peng ◽  
Weifang Liang ◽  
...  

2012 ◽  
Vol 51 (2) ◽  
pp. 173-176 ◽  
Author(s):  
Toru Miyoshi ◽  
Atsushi Hiraoka ◽  
Satoshi Hidaka ◽  
Yuko Shimizu ◽  
Keiko Ninomiya ◽  
...  

2002 ◽  
Vol 46 (8) ◽  
pp. 2525-2532 ◽  
Author(s):  
S. Levine ◽  
D. Hernandez ◽  
G. Yamanaka ◽  
S. Zhang ◽  
R. Rose ◽  
...  

ABSTRACT Entecavir (ETV) is a potent and selective inhibitor of hepatitis B virus (HBV) replication in vitro and in vivo that is currently in clinical trials for the treatment of chronic HBV infections. A major limitation of the current HBV antiviral therapy, lamivudine (3TC), is the emergence of drug-resistant HBV in a majority of treated patients due to specific mutations in the nucleotide binding site of HBV DNA polymerase (HBV Pol). To determine the effects of 3TC resistance mutations on inhibition by ETV triphosphate (ETV-TP), a series of in vitro studies were performed. The inhibition of wild-type and 3TC-resistant HBV Pol by ETV-TP was measured using recombinant HBV nucleocapsids, and compared to that of 3TC-TP. These enzyme inhibition studies demonstrated that ETV-TP is a highly potent inhibitor of wild-type HBV Pol and is 100- to 300-fold more potent than 3TC-TP against 3TC-resistant HBV Pol. Cell culture assays were used to gauge the potential for antiviral cross-resistance of 3TC-resistant mutants to ETV. Results demonstrated that ETV inhibited the replication of 3TC-resistant HBV, but 20- to 30-fold higher concentrations were required. To gain further perspective regarding the potential therapeutic use of ETV, its phosphorylation was examined in hepatoma cells treated with extracellular concentrations representative of drug levels in plasma in ETV-treated patients. At these concentrations, intracellular ETV-TP accumulated to levels expected to inhibit the enzyme activity of both wild-type and 3TC-resistant HBV Pol. These findings are predictive of potent antiviral activity of ETV against both wild-type and 3TC-resistant HBV.


Sign in / Sign up

Export Citation Format

Share Document